MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions
View by Date
Jump to:  View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z
  • D2 receptor mediated DARPP32/PP1α signaling is responsible for cadmium induced Parkinson’s like behavioral alterations in rats

    R. Gupta, R. Shukla, V. Khanna (Luckno, India)

  • Data driven analysis for exploring phenotypic differences in patients with Parkinson’s disease with or without genetic mutations.

    A. Mirelman, T. Kozlovski, A. Thaler, A. Mitelpunkt, T. Gurevich, M. Kestenbaum, Z. Gan Or, M. Gana-Weisz, A. Bar-Shira, A. Orr-Urtreger, S. Bressman, K. Marder, M. Marcus-Kalish, Y. Benjamini, N. Giladi (Tel Aviv, Israel)

  • DaTscan in clinical evaluation of Multiple System Atrophy

    P. Khemani, S. Vernino (Dallas, TX, USA)

  • DBS Plus: Investigating cell therapy and deep brain stimulation as an approach to alter disease progression and treat motor and non-motor symptoms of Parkinson’s disease

    C. van Horne, J. Quintero, J. Gurwell, A. Anderson-Mooney, A. Welleford, J. Lamm, J. Slevin, G. Gerhardt (Lexngton, KY, USA)

  • Death in patients with Parkinson’s disease – an observational study

    R. Mappilakkandy, A. Pieris, D. Miodrag, A. Chunduri (Northampton, United Kingdom)

  • Decision making under uncertainty in medicated and un-medicated Parkinson’s disesase

    J. Corrow, M. Cherkasova, A. Taylor, J. Stoessl, M. McKeown, S. Apple Creswell, J. Barton (Vancouver, BC, Canada)

  • Decision-making process for opicapone’s bedtime regimen

    A. Falcão, A. Santos, J. Ferreira, A. Lees, B. Hernandez, F. Rocha, P. Soares-da-Silva (Coimbra, Portugal)

  • Decisional capacity for Goals of Care in Parkinson’s Disease with Cognitive Concerns

    M. Abu Snineh, R. Camicioli, J. Miyasaki (Jerusalen, Israel)

  • Decreased Fronto-Parietal connection is associated with face pareidolia in Parkinson’s disease.

    Y. Kajiyama, M. Mihara, Y. Mitani, H. Otomune, H. Fujimoto, G. Revankar, K. Konaka, H. Mochizuki (Osaka, Japan)

  • Deep brain recording and surgical time in stereotactic and functional neurosurgery for movement disorders

    J. Teijeiro Amador, R. Macías, C. Maragoto, N. Quintanal (Havana, Cuba)

  • Deep Brain Stimulation (DBS) battery longevity of Medtronic Activa SC is briefer than preceding Soletra models, a within subject analysis

    E. Hargreaves, R. Patel, R. DiPaola, S. Wong, D. Caputo, S. Danish (New Brunswick, NJ, USA)

  • Deep Brain Stimulation (DBS) for Parkinson Disease in the Philippines: Outcomes and Practice of the First DBS Center

    J.D. Diestro, T. Vesagas, J. Aguilar, R. Teleg, J. Anlacan, R.D. Jamora (Manila, Philippines)

  • Deep Brain Stimulation and Olfactory Function in Parkinson’s Disease

    O. Saatci, B. Polat, N. Helvaci Yilmaz, T. Zirh (Istanbul, Turkey)

  • Deep Brain Stimulation for Parkinson Disease before L-dopa treatment: experience in three cases.

    d. servello, M. Porta, e. zekaj (Milano, Italy)

  • Deep Brain Stimulation for Parkinson’s disease: Short-term outcomes, referral patterns and health disparities.

    D. Di Luca, V. Aldahondo, W. Jermakowicks, L. Segala, H. Moore, C. Singer, B. Levin, J. Jagid, C. Luca (Miami, FL, USA)

  • Deep Brain Stimulation in a case with Parkinsonism and SCA2 mutation: case report highlighting challenges and outcome

    N. Sarangmat, A. Whone, S. Gill, C. Robbins (Bristol, United Kingdom)

  • Deep brain stimulation in Parkinson’s disease: Outcome after more than nine years

    B. Thomsen, S. Jensen, A. Clausen, B. Jespersen, M. Karlsborg, A. Løkkegaard (Copenhagen, Denmark)

  • Deep brain stimulation influences on event-related potentials (P300) in Parkinson’s disease

    M. Zibetti, S. Palermo, S. Vighetti, A. Romagnolo, L. Lopiano (Torino, Italy)

  • Deep Brain Stimulation of Subthalamic Nucleus Selectively Modulates Striato-Thalamo-Cortical Circuit in Parkinson’s Disease: a Systematic Review and ALE Meta-analysis

    H. Chen (Beijing, China)

  • Deep Learning in Objective Classification of Spontaneous Movement of Patients with Parkinson’s Disease Using Large-Scale Free-Living Sensor Data

    F. Pfister, D. Kulić, T. Um, D. Pichler, A. Ahmadi, M. Lang, G. König, F. Achilles, S. Endo, K. Abedinpour, K. Ziegler, K. Bötzel, S. Hirche, A. Ceballos-Baumann, U. Fietzek (Munich, Germany)

  • Defective visual perception in patients with Lewy body disease: assessment of hallucinations with pareidolia test.

    Y. Higashi, T. Tabuchi, M. Tabata (Himeji, Japan)

  • Deferiprone combined with phlebotomy for aceruloplasminemia

    L.H.P. Vroegindeweij, J.G. Langendonk, J.H.P. Wilson, A.J.W. Boon (Rotterdam, Netherlands)

  • Degree, onset and longevity of benefit achieved with Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) as assessed by the UPDRS.

    D. Caputo, O. Mark, D. Schneider, R. DiPaola, S. Danish, E. Hargreaves (New Brunswick, NJ, USA)

  • Delayed progressive spastic cerebellar ataxia and cerebellar atrophy after Heat Stroke

    D. Desai, S. Desai, C. Sapre (Anand, India)

  • Delusional Misidentification Syndrome for “Self” in two patients with Parkinson`s Disease.

    S. Ray, D. Park, D. Burdick, A. Griffith, J. Shaw, P. Agarwal (Kirkland, WA, USA)

  • Demographic and Clinical Characteristics and Tetrabenazine (TBZ) Persistence in Patients With Huntington Disease (HD)-Associated Chorea

    V. Sung, R. Iyer, S. Gandhi, V. Abler, B. Davis, D. Irwin, K. Anderson (Birmingham, AL, USA)

  • Demographic and Clinical Characters of Parkinson’s Disease in Tertiary Hospital in Kuwait

    W. Kamel, J. Al Hashel, S. Ahmed (Kuwait, Kuwait)

  • Depression among Inpatients with Huntington’s Disease: Patient Characteristics and Outcomes

    F.S. Benesh, S. Gupta, V. Sung (Birmingham, AL, USA)

  • Depression and Cognitive Performance in Patients with Parkinson’s Disease

    A.J. Jacob, S. OJ, S. K, G. Kumarpillai (Bangalore, India)

  • Depression, anxiety and quality of life in Multiple System Atrophy

    L. Zhang, B. Cao, Q. Wei, R. Ou, B. Zhao, J. Yang, Y. Wu, H. Shang (Chengdu, China)

  • Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease

    A. Verma, V. Kumar, U. Singh (Allahabad, India)

  • Design and personalisation of new upper-limb dynamic orthoses for dystonia and dyskinesia

    L. Garavaglia, M. Ferari, A. Lo Mauro, E. Pagliano, G. Baranello, B. Bassi, A. Aliverti, S. Pittaccio (Lecco, Italy)

  • Design of a randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxin treatment for cervical dystonia (StimTox-CD)

    H. Drechsel, U. Malzahn, C. Roeser, P. Heuschmann, J. Volkmann (Würzburg, Germany)

  • Detection of Early Changes in Microbiota Composition in Prodromal Parkinson’s Disease

    J. Boertien, T. Van Laar (Groningen, Netherlands)

  • Determinant factors of treatment adherence in Parkinson’s disease

    I. Estrada-Bellmann, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías, P. Cortés-Estrada (Monterrey, Mexico)

  • Determinants of balance confidence and concern about falling in people with Parkinson’s disease

    L. Almeida, G. Valenca, E. Pinto, J. Oliveira-Filho (Salvador, Brazil)

  • Determinants of health-related quality of life in children and young adults with dystonia

    H. Eggink, M. Coenen, A. Elema, W. Veenstra, K. Peall, D. Sival, M. Tijssen (Groningen, Netherlands)

  • Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study

    J. Jimenez-Shahed, H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, W. Ondo, K. Anderson (Houston, TX, USA)

  • Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia

    J. Jimenez-Shahed, H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, W. Ondo, K. Anderson (Houston, TX, USA)

  • Developing a guide to facilitate involving people with Parkinson’s and their carers in service improvement

    N. Shaw, V. Evans, J. Rideout, C. Carroll (Plymouth, United Kingdom)

  • Development and validation of an alternative version of the Parkinson’s Disease-Cognitive Rating Scale

    R. Fernandez-Bobadilla, S. Martinez-Horta, J. Marin-Lahoz, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

  • Development and validation of diagnostic criteria for advanced Parkinson disease: the CDEPA questionnaire

    M.-R. Luquin, J. Kulisevsky, P. Martinez-Martin, P. Mir, E. Tolosa, P. Garcia-Delgado (Pamplona, Spain)

  • Development of a Clinical Outcomes Assessment (COA) in Pantothenate-Kinase Associated Neurodegeneration (PKAN): Item Generation and Clinimetric Properties

    R. Marshall, A. Collins, M. Escolar, H.A. Jinnah, T. Klopstock, M. Kruer, A. Videnovic, A. Robichaux-Viehoever, L. Swett, D. Revicki, R. Bender, W. Lenderking (Cambridge, MA, USA)

  • Development of a Clinician-reported Screening Tool to Identify Patients with Parkinson’s disease inadequately controlled on oral medications

    A. Antonini, P. Schmidt, P. Odin, L. Kleinman, A. Skalicky, K. Sail, Y. Jalundhwala, J. Zamudio, K. Onuk, T. Marshall, H. Fernandez (Venice, Italy)

  • Development of a New Kinematic Model for Head and Neck Movement Assessment in Cervical Dystonia

    A. Castagna, D. Anastasi, A. Crippa, L. Lanzotti, A. Montesano, A. Marzegan (Milano, Italy)

  • Development of a Paroxysmal Movement Disorder Diary for Patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

    R. Hall, S. Kilgariff, P. Collins, M. Brandabur, R. Arbuckle, A. Bowden (Macclesfield, United Kingdom)

  • Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy

    E. Rockenstein, G. Ostroff, F. Dikengil, F. Rus, M. Mante, J. Florio, A. Adame, I. Trinh, E. Masliah, R. Rissman (La Jolla, CA, USA)

  • Development of nano-formulation containing crocetin for the protective and beneficial effect against 6-hydroxydopamine induced Parkinson’s disease model via altered the genetic backgrounds

    V. Kumar, A. Verma, P. Bhatt (Allahabad, India)

  • Development of utility to evaluate a symptomatic diary of motor fluctuations of Parkinson’s disease (PD) using a smartphone application.

    H. Ohtsubo, H. Iwaki, H. Yabe, M. Nagai, M. Nomoto (Matsuyama Ehime, Japan)

  • Dextrometorphan/quinidine in Atypical Parkinsonisms and Huntington Disease

    J. Etcheverry, M. Cesarini, G. Rojas, E. Gatto (Buenos Aires, Argentina)

  • Diabetes Mellitus and Parkinson’s Disease

    G. Pagano, S. Polychronis, H. Wilson, F. Niccolini, M. Politis (London, United Kingdom)

  • Diagnosis of Irritable Bowel Syndrome Increases Risk of Parkinson’s Disease in the Finnish Population

    T. Mertsalmi, E. Pekkonen, F. Scheperjans (HUS, Finland)

  • Diagnostic utility of regional [18F]AV-1451 tau-PET measurements in PSP

    J. Whitwell, V. Lowe, N. Tosakulwong, S. Weigand, M. Senjem, C. Schwarz, A. Spychalla, R. Petersen, C. Jack, K. Josephs (Rochester, MN, USA)

  • Diaphragmatic myoclonus successfully treated with Botulinum toxin A

    Y. He, B. Li, Y. Pan, X. Zhang, L. Jin (Shanghai, China)

  • Differences between Hemifacial spasm with or without neurovascular conflict. Therapeutic implications with botulinum toxin type A.

    J.S. Bestoso, L. Ciancaglini, C. Stefani, C. Azcona, M.L. Contartese, A. Pappolla, J.I. Rojas, D. Bauso (Buenos Aires, Argentina)

  • Differences in cerebral perfusion between Major depression disorder and depression with Parkinson’s disease : Brain HMPAO SPECT study using SPM analysis

    Y.-D. Kim, Y.-D. Kim (Incheon, Republic of Korea)

  • Differences in the oscillatory activity of the globus pallidus in dystonia, parkinson´s disease and gilles de la tourette syndrome

    M.M. Carmona-Abellan, M. Valencia, J. Guridi, R. Luquin, J. Artieda, M. Alegre (Pamplona, Spain)

  • Differential diagnosis and progress monitoring in Progressive Supranuclear Palsy – a potential role of pulmonary function tests

    G. Nuebling, C. Abright, M. Schuberth, S. Schoenecker, K. Boetzel, J. Levin, S. Lorenzl (Munich, Germany)

  • Differential diagnosis of Parkinson’s Disease and Progressive Supranuclear Palsy

    Y. Trufanov (Kyiv, Ukraine)

  • Differential effects of ventral or dorsal predominant dopaminerjic denervation of striatum on development of dopamine dysregulation syndrome and punding in a rat model of parkinsonism

    E. Özkan, G. Çakmaklı, B. Elibol, E. Topçuoğlu (Ankara, Turkey)

  • Differential Item Functioning in the Unified Dyskinesia Rating Scale (UDysRS)

    S. Luo, G. Stebbins, Y. Liu, C. Goetz (Houston, TX, USA)

  • Differential microRNA expression in a cohort of Parkinson’s disease patients

    A. Garvey, N. Cutfield, J. Williams (Dunedin, New Zealand)

  • Differential peculiarities of cognitive disorders in Parkinson’s disease dementia and Vascular dementia

    V. Mykhaylov, I. Zdesenko (Kharkiv, Ukraine)

  • Differentiating Parkinsonism with Spatio-temporal dynamics (real-time MRI) and Acoustics of Speech (spectrogram)

    S. GUDWANI, S.S. Kumaran, M. Behari (New Delhi, India)

  • Difficulties in executing the MDS recommendations in the brazilian population

    E. Carreira, E. CARREIRA, A. PRADO, N. BRAZ, F. TAVARES, N. ROCHA, L. DE SOUZA, F. CARDOSO, A. TEIXEIRA (Belo Horizonte, Brazil)

  • Diffusion tensor imaging changes in the corpus callosum and cognitive impairment in Parkinson’s disease

    I. Bledsoe, D. Merkitch, G. Stebbins, B. Bernard, J. Goldman (San Francisco, CA, USA)

  • Diffusion Weighted Magnetic Resonance Imaging in Child Cerebral Palsy with Symptomatic Epilepsy

    k. aminov (tashkent, Uzbekistan)

  • Diffusion-Weighted MRI discriminates Parkinson´s Disease from the Parkinsonian Variant of Multiple System Atrophy: a Meta-analysis

    S. Bajaj, F. Krismer, G. Wenning, W. Poewe, K. Seppi (Innsbruck, Austria)

  • Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.

    M. Marano, M. Marano, L. di Biase, R. Arca, G. Cossu, E. Coletta, V. Di Lazzaro, A. Fasano, P. Marano (Rome, Italy)

  • Diplopia:  An Interesting Complication of Dropped Head Syndrome

    W. Deeb, I. Malaty (Gainesville, FL, USA)

  • Direct dopaminergic responsiveness of activity performance

    P. Hagell, G.-M. Hariz, B. Sandlund (Kristianstad, Sweden)

  • Directional distribution of subthalamic nucleus beta activity in patients with Parkinson’s disease

    G. Tinkhauser, A. Pogosyan, I. Debove, A. Nowacki, H. Tan, K. Petermann, K. Seidel, M. Oertel, C. Pollo, P. Brown, M. Schuepbach (Oxford, United Kingdom)

  • Disability-Adjusted Life Years (DALY) in X-linked Dystonia Parkinsonism

    P. Acuna, C. Go (Charlestown, MA, USA)

  • Disappearance of the clinical and imaging manifestations in Wilson’s disease after controlled therapy with tetrathiomolybdate and zinc

    I. Posada, C. Garfia, F. Ostos, A. Ramos (Madrid, Spain)

  • Disease modeling for Perry syndrome using patient induced pluripotent stem cells

    T. Mishima, T. Ishikawa, K. Imamura, T. Kondo, Y. Koshiba, R. Takahashi, J. Takahashi, A. Watanabe, N. Fujii, Y. Tsuboi, H. Inoue (Fukuoka, Japan)

  • Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study

    H. Fernandez, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, R. Hauser (Cleveland, OH, USA)

  • Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil

    L. Tönges, L. Tatenhorst, J. Koch, T. Outeiro, M. Zweckstetter, M. Bähr, P. Lingor (Bochum, Germany)

  • Disease-modifying effect of Zonisamide with the induction of BDNF and TrkB expression

    N. Kanzato (Haebaru-cho, Japan)

  • Disparities in Access to DBS Surgery Based on Demographics of Patients with PD Admitted for DBS Surgery in the United States from 2003 to 2013

    F.S. Benesh, S. Gupta, V. Sung (Birmingham, AL, USA)

  • Displacement of deep brain stimulation (DBS) lead location after implantation: Preliminary result of a study comparing early Vs late CT findings

    X.-L. Zhu, C. Lau, C.-M. Cheung, D. Chan, A. Chan, V. Mok, J. Yeung, W. Poon (Hong Kong, China)

  • Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms

    E. Mc Govern, O. Killian, S. Narasimham, B. Quinlivan, I. Beiser, L. Williams, R. Beck, J. Butler, S. O'Riordan, R. Reilly, M. Hutchinson (Dublin, Ireland)

  • Distinct pattern of striatal dopaminergic depletion in patients with parkin mutation

    K.-Y. Kwon (Seoul, Republic of Korea)

  • Distinguishing Subclinical Postural Instability in Early-stage Parkinson disease and postural instability of normal elderly using Sensory Organization Test and Limit of Stability

    S.-K. Lee, J.-H. Park (Bucheon, Republic of Korea)

  • Do Acetylcholinesterase Inhibitors (AChEI) delay institutionalisation in Parkinson’s and Lewy Body Disease?

    L. Brown, B. Mohamed, E. Thomas (Cardiff, United Kingdom)

  • Do median-nerve evoked blink reflexes allow early differentiation between PD and PSP in patients with debuting parkinsonism?

    E. Nordh, J. Linder, L. Forsgren (UMEA, Sweden)

  • Do motor symptoms influence on malnutrition in Parkinson`s disease patients?

    S. Tomic, V. Pekic, Z. Popijac, T. Pucic, M. Petek, T. Gilman Kuric (Osijek, Croatia)

  • Does cerebellar dysfunction contribute to tremor in Parkinson’s disease?

    E. Batzianouli, M. Pagliaro, D. Benninger (Lausanne, Switzerland)

  • Does gender influence the expression of non-motor symptoms in Parkinson’s disease?: An observational study

    J. Herreros Rodríguez, A. Esquivel López, R. Gordo Mañas, Á. Sánchez Ferro (Madrid, Spain)

  • Does levodopa-carbidopa intestinal gel in Parkinson’s disease patients increase the risk on polyneuropathy?

    H. Moes, M. Drent, T. Laar (Groningen, Netherlands)

  • Does Parkinsons KinetiGraph (PKG) recording help in clinical decision making? A local experience

    N. Wilson, R. Mappilakkandy, M. Smith, K. Nithi (Northampton, United Kingdom)

  • Does smoking impact dopamine neuronal loss in de novo Parkinson’s disease?

    Y. Lee, H.s. Yoo, S.J. Chung, P.H. Lee, Y.H. Sohn (Seoul, Republic of Korea)

  • Does the side of onset affect motor and non-motor symptoms in Parkinson’s disease?

    J. Silva, A. D'Abreu (Campinas, Brazil)

  • Domain-Specific Cognitive Impairment in Non-Demented Parkinson’s Disease Psychosis

    J. Hinkle, K. Perepezko, C. Bakker, T. Dawson, V. Johnson, Z. Mari, C. Marvel, K. Mills, A. Pantelyat, O. Pletnikova, L. Rosenthal, M. Shepard, D. Stevens, J. Troncoso, J. Wang, G. Pontone (Baltimore, MD, USA)

  • Domain-specific impact of cerebral white matter hyperintensities on Parkinson’s disease cognitive functioning

    P. Linortner, S. Chernavsky, T. Hendershott, K. Poston (Palo Alto, CA, USA)

  • Dopamine agonist therapy mediates relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease.

    T. Turner, J. Renfroe, V. Hinson (Charleston, SC, USA)

  • Dopamine Agonists and Postural Disorders in Parkinson’s disease

    L. Ameghino, V. Bruno, M. Merello (Buenos Aires, Argentina)

  • Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson’s disease

    M. Gilat, P. Bell, K. Ehgoetz Martens, M. Georgiades, J. Hall, C. Walton, S. Lewis, J. Shine (Sydney, Australia)

  • Dopamine Normalizes Putamen to Insula Activation Shift During Choice Reaction Time Task in PD

    J. Kim, K. Zhang, S. YorkWilliams, M. Ua Cruadhlaoich, V. Menon, K. Poston (Palo Alto, CA, USA)

  • Dopamine replacement influences on postural motor learning in Parkinson disease

    S. Paul, G. Olivier, C. Walter, S. Schaefer, L. Dibble (Salt Lake City, UT, USA)

  • Dopamine replacement medication improves acquisition, retention, and transfer of skilled upper extremity movement in people with Parkinson Disease.

    S. Paul, C. Walter, G. Olivier, L. Dibble, S. Schaefer (Salt Lake City, UT, USA)

  • Dopamine substitution restores effective connectivity between prefrontal and premotor areas in Parkinson’s disease

    P. Loehrer, F. Nettersheim, F. Jung, I. Weber, C. Huber, T. Dembek, E. Pelzer, M. Tittgemeyer, L. Timmermann (Marburg, Germany)

  • Dopamine transporter imaging predicts motor response to dopaminergic therapy for patients with advanced Parkinson’s disease: Possible role in patient selection for subthalamic deep brain stimulation.

    A. Nakajima, Y. Shimo, S. Sekimoto, K. Kamagata, J. Takayuki, G. Oyama, A. Umemura, N. Hattori (Tokyo, Japan)

  • Dopamine transporter scan finding in patients with chorea.

    K. Kawabe, K. Miura, K. Ikeda, Y. Iwasaki (Tokyo, Japan)

  • Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment

    R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, R. Chaudhuri, T. Henriksen, T. van Laar, K. Spivey, S. Vel, A. Lees (Vienna, Austria)

  • Down-regulation of miR-9* in the peripheral leukocytes of Huntington’s Disease patients

    K.-H. Chang, Y.-R. Wu, C.-M. Chen (Taoyuan County, Taiwan)

  • Dr. Paula Coutinho’s Seminal Contributions to the Understanding of Machado-Joseph’s Disease

    P. Marques, H. Teive, F. Germiniani, B. Garcia (Curitiba, Brazil)

  • Dream content in Parkinson’s Disease

    V. Malgrati, F. Mancini, L. Manfredi, M. Lacerenza, A. Maggiolini (Milan, Italy)

  • Driving license and car accidents in patients with Parkinson’s disease

    M. Tomiyama, T. Ueno, H. Nishijima, T. Kon, R. Haga, Y. Funamizu, A. Arai, C. Suzuki, J. Nunomura, M. Baba (Aomori, Japan)

  • Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study

    S. Sharma, T. Simuni, B. Greco, K. Biglan, C. Tarolli, K. Hodgeman, D. Oakes, D. Penz (Rochester, NY, USA)

  • Drug-induced movement disorders: not a typical problem

    A. Vives-Rodriguez, A. Patel (New Haven, CT, USA)

  • Dural lymphatic vasculature in human superior saggital sinus: the brain drain

    N. Visanji, A. Lang, D. Munoz (Toronto, ON, Canada)

  • Dynamic Instability and Stride Width in Parkinsonism

    P. Fino, C. Curtze, M. Mancini, P. Carlson-Kuhta, J. Nutt, F. Horak (Portland, OR, USA)

  • Dynamic of symptoms of dopamine dysregulation syndrome after deep brain stimulation in patients with Parkinson`s disease

    S. Omarova, N. Fedorova, A. Tomskiy, A. Gamaleya, E. Bril, N. Gubareva (Moscow, Russian Federation)

  • Dynamic prediction of motor diagnosis in Huntington’s disease using a joint modeling approach

    K. Li, E. Furr Stimming, S. Luo, K. Li (Houston, TX, USA)

  • Dynamic stability during turning in people with Parkinson’s disease

    C. Curtze, P. Fino, S. Smith, P. Carlson-Kuhta, J. Nutt, F. Horak (Portland, OR, USA)

  • Dynamics of brain iron content and cortical pencil lining in healthy aging: An MRI study

    M. van_der Weijden, P.-J. van Laar, R. Lambrechts, D. Verbeek, M. Tijssen (Groningen, Netherlands)

  • Dynamics of subthalamic nucleus beta bursts in Parkinson’s disease during ON and OFF dopaminergic state

    G. Tinkhauser, A. Pogosyan, H. Tan, A. Kühn, P. Brown (Oxford, United Kingdom)

  • Dysphagia in PSP

    H. Clark, J. Whitwell, J. Ahlskog, K. Josephs (Rochester, MN, USA)

  • Dystonia due to bilateral caudate hemorrhage associated with a COL4A1 mutation

    T. Hatano, K. Daida, Y. Hoshino, Y. Li, H. Saitsu, N.c. Matsumoto, N. Hatter (Tokyo, Japan)

  • Dystonia Gravidarum Improved After Joint Position Error Training

    T. Pham, A. Elder, A. Wu (Los Angeles, CA, USA)

  • Dystonia treatment in an international cohort: a longitudinal analysis

    S. Pirio Richardson, A. Wegele, A. Deligtisch, F. Qeadan (Albuquerque, NM, USA)

  • Dystonia-like phenotype in a DYT1 rat model after peripheral trauma

    S. Knorr, K. Grundmann-Hauser, J. Volkmann, C.W. Ip (Wuerzburg, Germany)

Jump to:  View All • a b c [d] e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley